.
ER Editor: Weight loss treatments Ozempic and Wegovy, both GLP-1 drugs, are now being linked to pancreatitis. As far as we are aware, an inflammmatory condition in the pancreas may well lead to cancer later on.
Ozempic WAS being given as a diabetic drug originally before becoming the go-to treatment for weight loss (to boost flagging sales of an old drug? – notice the word ‘blockbuster’ below). Diabetes is a dysfunction of the pancreas, so does that mean Ozempic was causing a problem in the organ it was actually meant to fix? Notice how they say, ‘but it’s you who may have a genetic problem’, shifting the blame onto the patient. Notice also in the language of the article below that they don’t actually know if this is the case. Pure speculation while blaming the unwitting consumer. And they also blame ‘pre-existing conditions’. You couldn’t make this up.
Shouldn’t diabetics and obese people be fixing their problems with a healthy diet, intermittent fasting and exercise? What’s happened to us?
The Guardian also picked up this story —
Hundreds of weight loss and diabetes jab users report pancreas problems
According to our reading, drugs like Ozempic can cause a good many other serious reactions.
********
‘UK Probes Genetic Link Between Obesity Drugs and Pancreas Damage’; I warn again about these GLP-1 agonists, be careful, use under guidance, these were NEVER to be as weight loss drugs these were TYPE
II diabetes drugs; “GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects,” said Matt Brown, chief scientific officer …
UK Probes Genetic Link Between Obesity Drugs and Acute Pancreatitis – Bloomberg
There were 181 reports of acute or chronic pancreatitis in patients taking tirzepatide, the ingredient in Lilly’s Mounjaro and Zepbound, and 113 cases in patients taking semaglutide, sold under the brand names Wegovy and Ozempic, according to data from the regulator’s Yellow Card medical safeguard program.
Five cases were fatal in patients taking the Lilly medicines and one person on the Novo ones died.’
UK Probes Genetic Link Between Obesity Drugs and Pancreas Damage
- ‘The UK’s drug regulator and Genomics England are investigating whether genetics play a role in acute pancreatitis, a potential side effect of obesity drugs like Wegovy and Zepbound.
- Patients who were hospitalized with acute pancreatitis while taking GLP-1 drugs are being asked to report to the Yellow Card Biobank to help understand the genetic risk.
- There were 181 reports of pancreatitis in patients taking Lilly’s tirzepatide and 113 cases in patients taking Novo’s semaglutide, with five fatalities reported in patients taking Lilly medicines and one in patients taking Novo medicines.’
The UK is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to come in for tests to understand whether there’s a genetic risk for the condition.
The country’s drug regulator, alongside Genomics England, is investigating whether a person’s genetics might make them more vulnerable to acute pancreatitis — a potential serious side effect of Novo Nordisk A/S and Eli Lilly & Co.’s blockbusters.
In a public announcement, the two agencies called for people who were hospitalized with the condition while taking GLP-1 drugs to report it to a program called the Yellow Card Biobank.
Novo said it continues to collect safety data about its GLP-1 drugs, which include Ozempic for diabetes.
“Patient safety is of the utmost importance,” it said by email. “We recommend that patients take these medications only for their approved indications and under the strict supervision of a health-care professional.”
Lilly said adverse events can be caused by other factors, including pre-existing conditions. The US drugmaker echoed Novo’s comments on safety and talking to a doctor, especially for people who have already had pancreatitis.
Both companies sell two drug versions with the same active ingredient, one for diabetes and the other for obesity.
The pancreas, a long gland tucked behind the stomach, can become inflamed quickly and require urgent medical attention. While most cases improve quickly, some patients can develop complications and even die from the condition.
Making Headlines
“GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects,” said Matt Brown, chief scientific officer at Genomics England. “We believe there is real potential to minimize these with many adverse reactions having a genetic cause.”
There were 181 reports of acute or chronic pancreatitis in patients taking tirzepatide, the ingredient in Lilly’s Mounjaro and Zepbound, and 113 cases in patients taking semaglutide, sold under the brand names Wegovy and Ozempic, according to data from the regulator’s Yellow Card medical safeguard program.
Five cases were fatal in patients taking the Lilly medicines and one person on the Novo ones died. Reports to the program from patients, health professionals and drugmakers only indicate that a medicine is suspected to have resulted in the adverse reaction, and it doesn’t show causality.
Source
Featured image source, woman injecting: https://medicine.washu.edu/news/study-identifies-benefits-risks-linked-to-popular-weight-loss-drugs/
Featured image source, Wegoby: https://archive.md/RzpYU#selection-1609.0-1629.99
********
••••
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
••••
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
••••
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
••••
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Leave a Reply